首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   16494篇
  免费   1511篇
  国内免费   71篇
耳鼻咽喉   277篇
儿科学   624篇
妇产科学   374篇
基础医学   2124篇
口腔科学   424篇
临床医学   1144篇
内科学   3670篇
皮肤病学   619篇
神经病学   1001篇
特种医学   603篇
外国民族医学   6篇
外科学   2743篇
综合类   142篇
一般理论   2篇
预防医学   1232篇
眼科学   431篇
药学   1432篇
中国医学   97篇
肿瘤学   1131篇
  2023年   129篇
  2022年   445篇
  2021年   685篇
  2020年   434篇
  2019年   702篇
  2018年   902篇
  2017年   641篇
  2016年   666篇
  2015年   590篇
  2014年   856篇
  2013年   1147篇
  2012年   1311篇
  2011年   1429篇
  2010年   903篇
  2009年   780篇
  2008年   830篇
  2007年   797篇
  2006年   766篇
  2005年   611篇
  2004年   573篇
  2003年   392篇
  2002年   377篇
  2001年   298篇
  2000年   319篇
  1999年   236篇
  1998年   97篇
  1997年   75篇
  1996年   67篇
  1995年   43篇
  1994年   44篇
  1993年   36篇
  1992年   36篇
  1991年   35篇
  1990年   26篇
  1989年   28篇
  1988年   32篇
  1987年   24篇
  1985年   28篇
  1984年   84篇
  1983年   72篇
  1982年   45篇
  1981年   32篇
  1980年   48篇
  1979年   51篇
  1978年   46篇
  1977年   40篇
  1976年   39篇
  1975年   43篇
  1974年   24篇
  1973年   19篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
BackgroundTotal hip and knee arthroplasties are increasingly performed operations, and routine follow-up places huge demands on orthopedic services. This study investigates the effectiveness, patients’ satisfaction, and cost reduction of Virtual Joint Replacement Clinic (VJRC) follow-up of total hip arthroplasty and total knee arthroplasty patients in a university hospital. VJRC is especially valuable when in-person appointments are not advised or feasible such as during the COVID-19 pandemic.MethodsA total of 1749 patients who were invited for VJRC follow-up for knee or hip arthroplasty from January 2017 to December 2018 were included in this retrospective study. Patients were referred to VJRC after their 6-week postoperative review. Routine VJRC postoperative review was undertaken at 1 and 7 years and then 3-yearly thereafter. We evaluated the VJRC patient response rate, acceptability, and outcome. Patient satisfaction was measured in a subgroup of patients using a satisfaction survey. VJRC costs were calculated compared to face-to-face follow-up.ResultsThe VJRC had a 92.05% overall response rate. Only 7.22% required further in-person appointments with only 3% being reviewed by an orthopedic consultant. VJRC resulted in an estimated saving of £42,644 per year at our institution. The patients’ satisfaction survey showed that 89.29% of the patients were either satisfied or very satisfied with VJRC follow-up.ConclusionVJRC follow-up for hip and knee arthroplasty patients is an effective alternative to in-person clinic assessment which is accepted by patients, has high patient satisfaction, and can reduce the cost to both health services and patients.  相似文献   
2.
Quality of Life Research - The aim of the study was to assess QoL and identify and analyse its determinants in women with endometriosis. The study was performed in 2019 in health centres in Lublin...  相似文献   
3.
4.
5.

Background

The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.

Methods

Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.

Results

Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.

Conclusions

No safety concerns arose, supporting the favorable benefit-risk profile of RZV.  相似文献   
6.
7.
8.
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号